Physician profile
Debra Harmady
NPI 1053383455
$436.61
in general payments reported to CMS, 2019-2025
12 companies · $97.77 in 2025
The $97.77 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.96 · 2020: $11.82 · 2021: $27.64 · 2022: $55.15 · 2023: $121 · 2024: $65.50 · 2025: $97.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $100.63 | 2023 | Vyjuvek |
| Cumberland Pharmaceuticals, INC. | $94.94 | 2024-2025 | Kristalose |
| Sanofi Pasteur INC. | $68.15 | 2019-2024 | |
| Genentech USA, INC. | $41.28 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $33.01 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $16.82 | 2025 | Zoryve |
| Kaleo, INC. | $14.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.55 | 2025 | |
| Corium, LLC | $14.14 | 2022 | |
| Hologic Sales and Service, LLC | $13.56 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.65 | 2021 | |
| Neos Therapeutics, Lp | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Harmady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.